Rhumbline Advisers Cure Vac N.V. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$13.18 - $19.41 $562,983 - $829,098	-42,715 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$14.73 - $35.25 $74,445 - $178,153	-5,054 Reduced 10.58%	42,715 $838,000
Q4 2021 Feb 10, 2022	BUY	$33.72 - $48.22 $47,309 - $67,652	1,403 Added 3.03%	47,769 $1.64 Million
Q3 2021 Nov 12, 2021	SELL	$49.26 - $74.5 $10,935 - $16,539	-222 Reduced 0.48%	46,366 $2.53 Million
Q2 2021 Aug 05, 2021	BUY	$56.91 - $127.53 $2.65 Million - $5.94 Million	46,588 New	46,588 $3.42 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.